FOR IMMEDIATE RELEASE
SparkCures Announces Engagement with Leading Global Cancer Center to Provide Clinical Trial Search Platform and Support Services for All Blood Cancer Indications
In collaboration with the Memorial Sloan Kettering Cancer Center (MSK)’s Clinical Research Innovation Consortium (CRIC), SparkCures will provide technology and navigation services for healthcare providers and patients across all blood cancer indications
Pittsburgh, Pennsylvania—February 13, 2025—SparkCures, a leading innovator in clinical trial navigation and patient engagement, is thrilled to announce a new collaboration through the Memorial Sloan Kettering Cancer Center’s (MSKCC) Clinical Research Innovation Consortium (CRIC). This collaboration will provide clinical trial navigation and support across all blood cancer indications for MSK providers, patients, and referring clinicians.
The clinical trial search platform will serve as a resource for MSK’s internal research teams to streamline searching and evaluation processes across all hematology (including myeloma, leukemia, lymphoma, and myelodysplastic syndromes as well as myeloproliferative neoplasms). By leveraging the platform’s advanced capabilities, MSK can ensure that existing and new patients are connected to the most relevant and promising trials, optimizing the alignment of cutting-edge research with individual patient needs.
This collaboration aims to address critical needs by bridging community-based care with the unparalleled expertise of MSK. With 85% of cancer care occurring at the community level, the platform will empower local physicians by providing fast and effective screeners tailored to their patient’s needs while enhancing MSK’s capacity to extend its reach.
This initiative aims to improve access to innovative treatments, foster stronger connections between community doctors and MSK’s resources, and facilitate meaningful conversations around clinical trials. Looking ahead, a patient-facing portal launching in Q1 of this year will expand this reach, enabling seamless trial searches at MSK for patients and providers across the US.
“We are excited for this collaboration. This innovative platform exemplifies our commitment to improving patient access to clinical trials and empowering healthcare professionals with the tools they need to make informed decisions. Together, we are making significant strides in the search for a cure for all blood cancers,” said Brian McMahon, Founder and CEO of SparkCures.
“The SparkCures team has customized its platform to help us find all trials a patient could potentially be eligible for in an easy efficient way,” reports Gunjan L. Shah, MD, a bone marrow transplant specialist and cellular therapist and Assistant Attending Physician at MSK. “Among the advantages, this facilitates discussions within our case meetings across all the hematologic malignancy services in a multidisciplinary fashion between the research teams, the trainees, and the clinical teams.
To access the portal, please go to https://mskcc.sparkcures.pro
About SparkCures:
SparkCures, LLC is a patient navigation and technology company focused on simplifying the process of exploring clinical trial options. Through innovative technology and personalized support, SparkCures empowers patients and their care partners to find, understand, and connect with eligible clinical trials across the US and worldwide. For more information, visit https://SparkCures.com.
.
Media Contact:
Contact: Avi Steindel
Title: Director of Non-Profit Partnerships
Email: avi@sparkcures.com
Direct: 412-880-7474
Website: SparkCures.com
